Drugs / piperaquine
piperaquine
Trials 71 · started per year
today
1
4
1
2
5
5
7
5
5
5
3
1
4
3
2
3
5
3
4
1
2
2004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 111 trials | ||||||
| Phase 1 | NCT07470424 | Jun 2026 → Jun 2027 expected | malaria | University of Oxford | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06172686 | Jan → Feb 2024 | malaria | Ifakara Health Institute | Unknown | No outcome recorded |
| Phase 1 | NCT05160363 | Feb → May 2022 | — | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 1 | NCT03542149 | Apr 2018 → Apr 2019 | malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 1 | NCT02568098 | Oct 2015 → Dec 2016 | — | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT02431637 | Apr 2015 → Sep 2016 | malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 1 | NCT02184637 | Jul 2014 → Apr 2015 | Plasmodium vivax malaria | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01958619 | Oct 2013 → Jan 2014 | malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 1 | NCT01853475 | Apr → Jul 2013 | malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 1 | NCT01660022 | Sep 2012 → May 2013 | — | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 1 | NCT01222962 | Mar → May 2010 | Plasmodium falciparum malaria | sigma-tau i.f.r. S.p.A. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04280692 | Aug 2022 → Dec 2025 | Plasmodium falciparum malaria | University of Oxford | Suspended | No outcome recorded |
| Phase 1/2 | NCT02836002 | Jun 2016 → Jun 2017 | malaria | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT05252845 | Jan → Jun 2023 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 2 | NCT05829187 | Nov → Dec 2022 | Plasmodium falciparum malaria | Syamsudin Abdillah,Ph.D, Pharm D | Completed | No outcome recorded |
| Phase 2 | NCT02909712 | Sep 2016 → Jan 2020 | malaria, parasitemia, poisoning | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 2 | NCT02198807 | Mar → Jul 2014 | Plasmodium falciparum malaria | Jomaa Pharma GmbH | Unknown | No outcome recorded |
| Phase 2/35 trials · 1 missed | ||||||
| Phase 2/3 | NCT04009343 | Jun 2019 → Aug 2020 overdue | Plasmodium falciparum malaria | Johns Hopkins Bloomberg School of Public Health | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT02461186 | Jun 2015 → Jun 2017 | Plasmodium falciparum malaria | University of Oxford | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT02083380 | Jul 2014 → Oct 2015 | Plasmodium falciparum malaria | Medicines for Malaria Venture | Completed | Missed primary |
| Phase 2/3 | NCT00941785 | Jul → Dec 2009 | malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 2/3 | NCT00561899 | Aug 2007 → Feb 2008 | malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 321 trials · 3 met primary · 1 missed | ||||||
| Phase 3 | NCT06962319 | Sep 2025 → Aug 2028 expected | malaria | Liverpool School of Tropical Medicine | Recruiting | No outcome recorded |
| Phase 3 | NCT05946642 | Jul 2023 → May 2024 | malaria | Malaria Consortium | Unknown | No outcome recorded |
| Phase 3 | NCT04844099 | Apr 2021 → Jun 2023 | malaria, sickle cell disease | Liverpool School of Tropical Medicine | Completed | Met primary |
| Phase 3 | NCT03923725 | Sep 2020 → Mar 2024 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 3 | NCT04147546 | Aug 2020 → Aug 2021 | Plasmodium falciparum malaria | Institut de Recherche en Sciences de la Sante, Burkina Faso | Completed | No outcome recorded |
| Phase 3 | NCT04158713 | Nov 2019 → Apr 2022 | — | Liverpool School of Tropical Medicine | Completed | No outcome recorded |
| Phase 3 | NCT03671109 | Sep 2019 → Jul 2022 | HIV infectious disease, malaria, pregnancy disorder | Barcelona Institute for Global Health | Completed | Missed primary |
| Phase 3 | NCT03576313 | Aug 2018 → Dec 2019 | malaria | London School of Hygiene and Tropical Medicine | Completed | Mixed |
| Phase 3 | NCT03208907 | Jul 2018 → Jul 2021 | Plasmodium vivax malaria | Fundação de Medicina Tropical Dr. Heitor Vieira Dourado | Completed | No outcome recorded |
| Phase 3 | NCT01899820 | Apr 2013 → Jun 2014 | malaria | Sabah Ahmed Omar | Unknown | No outcome recorded |
| Phase 3 | NCT01722539 | Nov 2012 → Nov 2013 | — | University of Antwerp | Completed | No outcome recorded |
| Phase 3 | NCT01640574 | Feb 2012 → Jul 2015 | Plasmodium vivax malaria | University of Oxford | Completed | No outcome recorded |
| Phase 3 | NCT01231113 | Jul 2011 → Dec 2012 | Plasmodium falciparum malaria | Kwame Nkrumah University of Science and Technology | Completed | No outcome recorded |
| Phase 3 | NCT01231880 | Feb 2011 → Sep 2012 | malaria | Makerere University | Completed | Mixed |
| Phase 3 | NCT01288820 | Jan 2011 → Apr 2012 | Plasmodium vivax malaria | University of Oxford | Completed | No outcome recorded |
| Phase 3 | NCT00948896 | Jun 2010 → Apr 2014 | malaria | University of California, San Francisco | Completed | Mixed |
| Phase 3 | NCT01082705 | Apr 2010 → Jun 2011 | Plasmodium falciparum malaria | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 3 | NCT01845701 | Mar 2010 → Apr 2014 | malaria | University of Yaounde 1 | Completed | Met primary |
| Phase 3 | NCT01054248 | Feb 2010 → Sep 2016 | malaria | University of Oxford | Completed | No outcome recorded |
| Phase 3 | NCT00682578 | Jul 2007 → Feb 2010 | Plasmodium falciparum malaria, Plasmodium vivax malaria | University of Oxford | Completed | Met primary |
| Phase 3 | NCT00393679 | Jul 2007 → Dec 2009 | malaria | Institute of Tropical Medicine, Belgium | Completed | Mixed |
| Phase 417 trials | ||||||
| Phase 4 | NCT07246525 | Sep 2026 → Sep 2029 expected | malaria | University of California, San Francisco | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06347471 | May 2024 → Nov 2025 | Plasmodium falciparum malaria | Infectious Diseases Research Collaboration, Uganda | Completed | No outcome recorded |
| Phase 4 | NCT06225297 | Jan → Dec 2024 | malaria | PATH | Suspended | No outcome recorded Stop: Business |
| Phase 4 | NCT05788094 | Jun 2023 → Feb 2026 overdue | Plasmodium vivax malaria | Shoklo Malaria Research Unit | Recruiting | No outcome recorded |
| Phase 4 | NCT05340153 | Apr → Dec 2022 | malaria | University of Yaounde 1 | Unknown | No outcome recorded |
| Phase 4 | NCT05294406 | Feb 2022 → Dec 2023 | malaria | Liverpool School of Tropical Medicine | Completed | No outcome recorded |
| Phase 4 | NCT04816461 | Jul 2021 → Jun 2023 | malaria | Institut de Recherche en Sciences de la Sante, Burkina Faso | Completed | No outcome recorded |
| Phase 4 | NCT02940756 | Mar 2017 → Jan 2018 | malaria | Ministry of Public Health, Democratic Republic of the Congo | Completed | No outcome recorded |
| Phase 4 | NCT02654912 | Feb 2016 → Jun 2020 | malaria | PATH | Completed | No outcome recorded |
| Phase 4 | NCT02324738 | Jan → May 2015 | — | University of Oxford | Completed | No outcome recorded |
| Phase 4 | NCT02325180 | Jan → Jun 2015 | Plasmodium falciparum malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 4 | NCT02575755 | Oct 2012 → Jul 2016 | Plasmodium falciparum malaria, pregnancy disorder | Papua New Guinea Institute of Medical Research | Unknown | No outcome recorded |
| Phase 4 | NCT01669941 | Aug 2012 → Oct 2014 | malaria, pregnancy disorder | Kenya Medical Research Institute | Completed | Mixed |
| Phase 4 | NCT01651416 | Jul → Dec 2012 | anemia, malaria | Centre for Global Health Research, Ghana | Completed | No outcome recorded |
| Phase 4 | NCT01389557 | Feb → Nov 2011 | malaria | Indonesia University | Completed | No outcome recorded |
| Phase 4 | NCT00902811 | Dec 2008 → Oct 2009 | Plasmodium falciparum malaria | Medecins Sans Frontieres, Netherlands | Unknown | No outcome recorded |
| Phase 4 | NCT00845533 | Aug → Dec 2007 | malaria | University of California, San Francisco | Completed | No outcome recorded |
| Phase not applicable11 trials · 2 met primary · 2 missed | ||||||
| — | NCT07281443 | Sep 2024 → Dec 2026 expected | Plasmodium falciparum malaria, parasitemia | Research Institute for Development | Active not recruiting | No outcome recorded |
| — | NCT04864444 | Jun 2021 → Dec 2022 | Plasmodium falciparum malaria | University of California, San Francisco | Completed | Missed primary |
| — | NCT03454048 | May → Nov 2018 | Plasmodium falciparum malaria | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT02329301 | Sep 2014 → Jun 2016 | Plasmodium falciparum malaria | PATH | Completed | No outcome recorded |
| — | NCT02001428 | Jul 2014 → Mar 2016 | Plasmodium falciparum malaria, Plasmodium vivax malaria | Gadjah Mada University | Completed | Missed primary |
| — | NCT01640587 | Nov 2013 → Mar 2017 | Plasmodium falciparum malaria | University of Oxford | Terminated | No outcome recorded |
| — | NCT01872702 | Apr 2013 → Jul 2017 | Plasmodium falciparum malaria | University of Oxford | Completed | Met primary |
| — | NCT01624337 | May 2012 → Aug 2014 | malaria | Armed Forces Research Institute of Medical Sciences, Thailand | Terminated | No outcome recorded |
| — | NCT01326754 | Aug 2011 → Jun 2012 | Plasmodium falciparum malaria | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| — | NCT00868465 | Apr 2009 → May 2010 | malaria | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT00157833 | Jul 2004 → Aug 2005 | Plasmodium falciparum malaria, Plasmodium vivax malaria | Menzies School of Health Research | Completed | Met primary |
| Comparator or background therapy47 trials | ||||||
| Phase 1 | NCT05930782 Comparator | Aug → Dec 2023 | malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 1 | NCT02614404 Background | Nov 2015 → Dec 2016 | Plasmodium falciparum malaria | HuLow | Completed | No outcome recorded |
| Phase 1 | NCT02543086 Background | Jul → Sep 2015 | Plasmodium falciparum malaria | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT02083406 Background | Jul 2014 | malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 1/2 | NCT02802813 Comparator | Jun 2016 → Jun 2018 | Plasmodium vivax malaria | University of Oxford | Completed | No outcome recorded |
| Phase 2 | NCT04661579 Background | Nov 2020 → Jun 2022 | Plasmodium falciparum malaria | PATH | Completed | Met primary |
| Phase 2 | NCT04609098 Background | Oct → Dec 2020 | Plasmodium falciparum malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 2 | NCT06036030 Comparator | Jan → Apr 2019 | Plasmodium falciparum malaria, Plasmodium vivax malaria | Syamsudin Abdillah,Ph.D, Pharm D | Completed | No outcome recorded |
| Phase 2 | NCT03697668 Comparator | Sep 2017 → Dec 2018 | Plasmodium falciparum malaria | Nurex S.r.l. | Unknown | No outcome recorded |
| Phase 2 | NCT02831023 Comparator | Jul 2016 → Jan 2017 | malaria | University of California, San Francisco | Completed | Met primary |
| Phase 2 | NCT01992900 Comparator | Nov 2013 → Jul 2015 | Plasmodium falciparum malaria | sigma-tau i.f.r. S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT01743820 Background | Sep 2013 → Dec 2014 | malaria | University of California, San Francisco | Completed | Met primary |
| Phase 2/3 | NCT04049916 Comparator | Sep 2019 → Jan 2020 | Plasmodium falciparum malaria | London School of Hygiene and Tropical Medicine | Completed | Met primary |
| Phase 2/3 | NCT02654730 Comparator | Dec 2015 → Sep 2016 | malaria | London School of Hygiene and Tropical Medicine | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT02453308 Comparator | Aug 2015 → Mar 2018 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 3 | NCT07798583 Comparator | Jan 2028 → Jan 2030 expected | malaria | Indiana University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07082205 Comparator | May 2025 → Sep 2026 overdue | anemia, malaria | Liverpool School of Tropical Medicine | Recruiting | No outcome recorded |
| Phase 3 | NCT06516042 Comparator | Aug 2024 → Jan 2025 overdue | Plasmodium falciparum malaria | PATH | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04978272 Comparator | Feb 2022 → May 2027 expected | malaria | Grant Dorsey, M.D, Ph.D. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03939104 Comparator | Jun 2021 → Jan 2023 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 3 | NCT04660110 Comparator | Jan → Jun 2021 | malaria | Makerere University | Unknown | No outcome recorded |
| Phase 3 | NCT04189744 Comparator | Dec 2019 → Oct 2022 | Trichomonas vaginitis urogenital infection, bacterial vaginosis, malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 3 | NCT04149106 Comparator | Jul 2019 → Dec 2022 | Plasmodium falciparum malaria | University Clinical Research Center, Mali | Unknown | No outcome recorded |
| Phase 3 | NCT03452475 Comparator | Mar 2018 → Jun 2019 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 3 | NCT02793622 Comparator | Sep 2016 → Dec 2018 | malaria | University of California, San Francisco | Completed | No outcome recorded |
| Phase 3 | NCT02671175 Comparator | May 2016 → Oct 2018 | anemia, malaria | Liverpool School of Tropical Medicine | Completed | No outcome recorded |
| Phase 3 | NCT02282293 Comparator | Dec 2014 → May 2016 | HIV infectious disease, malaria | University of California, San Francisco | Completed | No outcome recorded |
| Phase 3 | NCT01838902 Background | Aug 2013 → Feb 2015 | malaria | London School of Hygiene and Tropical Medicine | Completed | Met primary |
| Phase 3 | NCT02974348 Comparator | Jan → May 2013 | Plasmodium falciparum malaria | University of Bamenda | Completed | No outcome recorded |
| Phase 3 | NCT00852371 Comparator | Feb → Jun 2008 | malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 3 | NCT00529620 Comparator | Sep → Dec 2007 | malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 4 | NCT07403643 Background | Apr → Dec 2026 expected | malaria | Curtin University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06068530 Comparator | Feb 2025 → Feb 2028 expected | Plasmodium falciparum malaria | University of Oxford | Recruiting | No outcome recorded |
| Phase 4 | NCT04704999 Comparator | Jul 2024 → Oct 2027 expected | Plasmodium vivax malaria | University of Oxford | Recruiting | No outcome recorded |
| Phase 4 | NCT05323721 Comparator | Jun → Nov 2022 | malaria | Malaria Consortium | Unknown | No outcome recorded |
| Phase 4 | NCT05343312 Comparator | Mar 2022 → Sep 2023 | Plasmodium falciparum malaria | Manhiça Health Research Centre | Completed | No outcome recorded |
| Phase 4 | NCT04767191 Comparator | Mar 2021 → Dec 2022 | malaria | Jhpiego | Completed | No outcome recorded |
| Phase 4 | NCT03178643 Comparator | Jan 2018 → Dec 2020 | Plasmodium falciparum malaria | Duke University | Completed | No outcome recorded |
| Phase 4 | NCT02604966 Comparator | Apr 2015 → Sep 2016 | Plasmodium falciparum malaria | National Institute of Malariology, Parasitology and Entomology, Vietnam | Unknown | No outcome recorded |
| Phase 4 | NCT02434952 Background | Oct 2014 → Jul 2016 | G6PD deficiency, Plasmodium falciparum malaria | Malaria Consortium | Completed | No outcome recorded |
| Phase 4 | NCT02118090 Comparator | May → Dec 2014 | Plasmodium vivax malaria | Institut Pasteur, Cambodia | Completed | No outcome recorded |
| Phase 4 | NCT01930331 Comparator | Jan → Jul 2014 | Plasmodium falciparum malaria | Ifakara Health Institute | Completed | No outcome recorded |
| Phase 4 | NCT01887821 Comparator | Feb 2013 → Jun 2015 | Plasmodium vivax malaria | Oxford University Clinical Research Unit, Vietnam | Completed | No outcome recorded |
| Phase 4 | NCT01704508 Comparator | Nov 2012 → Oct 2015 | Plasmodium falciparum malaria | Bandim Health Project | Completed | No outcome recorded |
| Phase 4 | NCT01392014 Comparator | Dec 2008 → Mar 2010 | Plasmodium falciparum malaria | Indonesia University | Completed | No outcome recorded |
| — | NCT07533136 Comparator | May 2026 → Oct 2028 expected | Plasmodium vivax malaria | Walter Reed Army Institute of Research (WRAIR) | Not yet recruiting | No outcome recorded |
| — | NCT07389057 Comparator | Nov 2023 → Nov 2026 expected | Plasmodium falciparum malaria, parasitemia | Noguchi Memorial Institute for Medical Research | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2011-11-22 | Sanaria Inc. | Results Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission- blocking activity by methylene blue sanaria.com ↗
The other partner agents monodesethyl-amodiaquine and piperaquine showed activity only against immature gametocytes. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2011-11-22 | Sanaria Inc. | Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission- blocking activity by methylene blue sanaria.com ↗ |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 121 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Piperaquine | “At each ANC visit: treatment with Dihydroartemisinin-piperaquine for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women...” NCT01669941 ↗116“Open Label, Parallel Group Study to Investigate the Pharmacokinetics (PK) Following Oral Co-administration of Piperaquine Phosphate (PQP) Tablets With a Prototype OZ439 + TPGS...” NCT01853475 ↗ “Dihydroartemisinin/piperaquine tablets for adult patients each contain 40 mg dihydroartemisinin and 320 mg piperaquine with a therapeutic dose range between 2-10 mg/kg/day...” NCT05252845 ↗ “Our aim was to compare the safety and efficacy of dihydroartemisinin-piperaquine with that of artemether-lumefantrine in patients with uncomplicated malaria caused by...” PMID 17336652 ↗ Mar 2007 “Sixty patients received either dihydroartemisinin/piperaquine (4 mg/kg/day, 3 days; n = 33) or artesunate monotherapy (4 mg/kg/day, 3 days; n = 27) followed by...” PMID 32437557 ↗ Aug 2020 “The primary goal of the study is to compare 2 SMC regimens (SP-AQ and dihydroartemisinin-piperaquine [DHA-PQ]) in preventing uncomplicated Plasmodium falciparum malaria in...” PMID 38252481 ↗ Jan 2024 “Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of Ghana” NCT07389057 ↗ “The reactive response consists of treating all individuals within a defined radius of each RDT-confirmed incident malaria case with dihydroartemisinin-piperaquine (DHAP).” NCT02654912 ↗ “Piperaquine (320 mg per tablet) 16.8 g/kg daily for 3 days Du-Cotecxin ( 40mg dihydroartemisinin(DHA)/320mg piperaquine(PQP))PQP/DHA 1.6/12.8mg/kg once daily for 3 days” NCT00561899 ↗ “Pharmacokinetic and Mosquito-Lethal Effects of Ivermectin (IVM), Primaquine (PQ), Dihydroartemisinin-Piperaquine (DHA-PQP) and Albendazole (ABZ) in Healthy Subjects” NCT02568098 ↗ “Age- or weight-based dihydroartemisinin-piperaquine administered monthly for 24 months as intermittent preventive treatment in school-aged children (IPTsc).” NCT07798583 ↗ |
| Known as | PIP | “one tablet of DHA-PIP contains 40 mg of dihydroartemisinin (DHA) and 320 mg piperaquine (PIP).” NCT02118090 ↗ |
| Known as | Piperaquine Phosphate | “Bioavailability Study of Oral OZ439 Prototype Formulations Administered With Piperaquine Phosphate (PQP)” NCT02083406 ↗ |
| Known as | Piperaquine phosphate component of eurartesim piperaquine tetraphosphate | ChEMBL registry synonym — accepted as the source's own label CHEMBL303933 ↗ |
| Known as | Piperaquine tetraphosphate | “Piperaquine tetraphosphate 960 mg (three tablets)” NCT05160363 ↗ |
| Known as | Piperaquinoline | ChEMBL registry synonym — accepted as the source's own label CHEMBL303933 ↗ |
| Known as | PPQ | “In 2014-2015, a phase 2b clinical study was conducted to evaluate the efficacy of a single oral dose of Artefenomel (OZ439)-piperaquine (PPQ) in Asian and African patients...” PMID 30967148 ↗ Apr 20192“PPQ: Piperaquine will be administered according to an optimised dosing schedule using tablets of 160 or 500 mg of piperaquine tetraphosphate.” NCT03923725 ↗ “Dihydroartemisinin+ Paperaquine (DHA+PPQ, Artekin)” NCT00682578 ↗ |
| Known as | PQP | “Open Label, Parallel Group Study to Investigate the Pharmacokinetics (PK) Following Oral Co-administration of Piperaquine Phosphate (PQP) Tablets With a Prototype OZ439 + TPGS...” NCT01853475 ↗4“Piperaquine (320 mg per tablet) 16.8 g/kg daily for 3 days Du-Cotecxin ( 40mg dihydroartemisinin(DHA)/320mg piperaquine(PQP))PQP/DHA 1.6/12.8mg/kg once daily for 3 days” NCT00561899 ↗ “A novel oral combination of the long-acting antimalarials pyronaridine (PYR) and piperaquine (PQP) has potential for malaria chemoprevention.” PMID 40689586 ↗ Jul 2025 “single oral dose of piperaquine (PQP) in a dispersible granule formulation compared to the PQP hard tablet formulation” NCT05930782 ↗ “Bioavailability Study of Oral OZ439 Prototype Formulations Administered With Piperaquine Phosphate (PQP)” NCT02083406 ↗ |
| Modality | Small molecule | “It is a bisquinoline antimalarial drug (1,3-bis\[1-(7-chloro-4 quinolyl)-4- piperazinyl\]-propane) that was first synthesised in the 1960s” NCT01845701 ↗ |
| Route | Oral | “dihydroartemisinin-piperaquine at an estimated total dosing of 6.75mg/kg of dihydroartemisinin and 55mg/kg of piperaquine for 3 days rounded to the nearest half tablet)” NCT01231113 ↗ |